UNSPSC 51401568: Metaclazepam hydrochloride

This classification denotes a benzodiazepine with the molecular formula C18H18BrClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P21PFK193T, chemically known as 2,3-dihydro-7-bromo-5-(2-chlorophenyl)-2-(methoxymethyl)-1-methyl-1h-1,4-benzodiazepine hcl but more generally known as metaclazepam hydrochloride, which bears US NIH Compound Identifier 162950. European Medicines Agency schedules Metaclazepam hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03181MIG.

UNSPSC 51401568 Metaclazepam hydrochloride is a Commodity code with minimal alignment to recent state and local procurement activity. The code's nominal scope—a specific benzodiazepine pharmaceutical—does not match the substance of recent opportunities posted under this code number. The three most recent state and local solicitations tagged to this code address naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy benefit program, and generic multi-source pharmaceuticals with OTC products respectively. None of these procurements involve metaclazepam or target the narrow therapeutic category the code nominally describes. The mismatch suggests either upstream tagging errors or that this code is being used as a catch-all for broader pharmaceutical procurement activity rather than for the specific active pharmaceutical ingredient it names.

The issuing bodies soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note the date inconsistency in the source). The Texas Health and Human Services Commission issued an RFI on April 3, 2026, to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, contract effective date, serving participating state and local facilities including Oregon. Given the disconnect between the code's stated substance and the actual procurement scope, business development professionals should verify category assignment before pursuing opportunities under this code.